Zydus向Astallas支付120M美元,以解决Mirabegron专利争端,并在美国继续出售通用专利,直至2027年9月。 Zydus pays $120M to Astellas to settle Mirabegron patent dispute and keep selling generic in U.S. until Sept. 2027.

Zydus生命科学及其美国单位已同意向Astallas Pharma支付1.2亿美元,以解决有关膀胱药物Mirabegron的专利纠纷,使Zydus能够继续在美国出售其通用版本,直至2027年9月。 Zydus Lifesciences and its U.S. unit have agreed to pay $120 million to Astellas Pharma to settle a patent dispute over the bladder drug Mirabegron, allowing Zydus to continue selling its generic version in the U.S. until September 2027. 这笔交易包括预付的每单位销售许可证费,其他条件也保密。 The deal includes a prepaid per-unit licensing fee on sales, with other terms confidential. 达成和解之前,与对立的通用制造商Lupin达成了一项类似的9 000万美元的协议,可能会限制市场上的竞争。 The settlement follows a similar $90 million agreement with rival generic maker Lupin and may limit competition in the market.